Garidisan: Improving the Quality of Ulcer Healing in Rats with Ulcerative Colitis

Figure 1

Treatment efficacy of Garidisan in UC rats; (a) DAI for rats after UC modeling; (b) colonic mucosal damage indices for rats in different treatment groups; (c) HS for rats in different treatment groups. Note that (1) represents normal controls; (2) represents the UC model group; (3) represents the low-dose Garidisan group; (4) represents the moderate-dose Garidisan group; (5) represents the high-dose Garidisan group; (6) represents the SASP group; and (7) represents the Bupiyichangwan group; , , and compared with normal controls; , , and compared with the UC model group.

(a)

(b)

(c)